UPDATES FROM THE CLINICAL TRIAL PHASE

The research and development phase has finished. The peptides for the HEPAVAC vaccine’s cocktail have been selected and the production in according to GMP standards has been finalized at Bcn Peptides, a Spanish company focused on the GMP manufacture of Bioactive peptides for Pharmaceutical and Veterinary applications (http://www.bcnpeptides.com/).

The product manufacturing is currently underway at GP Pharma in Barcelona (http://gp-pharm.com/).

The clinical trial, according to our provisions, should start by the end of 2016.